Torrent Pharmaceuticals Intrinsic Value
Torrent Pharmaceuticals (TORNTPHARM) median intrinsic value is ₹1946.04 from 10 valuation models (range ₹1488–₹2850), vs current price ₹4961.50 — -60.8% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Torrent Pharmaceuticals share price today.
TORNTPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Torrent Pharmaceuticals intrinsic value across 10 models vs current price ₹4961.50 — upside/downside and value range per method. Analyse Torrent Pharmaceuticals ownership pattern to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1488.45 | ₹1190.76 - ₹1786.14 | -70.0% | EPS: ₹46.04, Sector P/E: 22x |
| Book Value Method | asset | ₹2081.07 | ₹1872.96 - ₹2289.18 | -58.1% | Book Value/Share: ₹1040.53, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1946.04 | ₹1751.44 - ₹2140.64 | -60.8% | Revenue/Share: ₹973.02, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2849.70 | ₹2564.73 - ₹3134.67 | -42.6% | EBITDA: ₹4816.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2322.95 | ₹1858.36 - ₹2787.54 | -53.2% | CF Growth: 13.8%, Discount: 15% |
| PEG Ratio Method | growth | ₹1488.45 | ₹1339.61 - ₹1637.30 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1488.45 | ₹1339.61 - ₹1637.30 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2480.75 | ₹2232.68 - ₹2728.83 | -50.0% | ROE: 8.3%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹1488.45 | ₹1339.61 - ₹1637.30 | -70.0% | EPS: ₹46.04, BVPS: ₹1040.53 |
| Dividend Yield Method | dividend | ₹1520.00 | ₹1368.00 - ₹1672.00 | -69.4% | DPS: ₹38.00, Target Yield: 2.5% |
TORNTPHARM Intrinsic Value vs Market Price — All Valuation Models
Torrent Pharmaceuticals fair value range ₹1488–₹2850 vs current market price ₹4961.50 across 10 valuation models. Read TORNTPHARM dividend track record for the complete payout history and dividend yield track record.
TORNTPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Torrent Pharmaceuticals median intrinsic value ₹1946.04, current price ₹4961.50 — Trading Above Calculated Value by 60.8%, margin of safety -100.0%.
What is the intrinsic value of TORNTPHARM?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Torrent Pharmaceuticals (TORNTPHARM) is ₹1946.04 (median value). With the current market price of ₹4961.50, this represents a -60.8% variance from our estimated fair value.
The valuation range spans from ₹1488.45 to ₹2849.70, indicating ₹1488.45 - ₹2849.70.
Is TORNTPHARM undervalued or overvalued?
Based on our multi-method analysis, Torrent Pharmaceuticals (TORNTPHARM) appears to be trading above calculated value by approximately 60.8%.
TORNTPHARM Financial Health — Key Ratios vs Industry Benchmarks
Torrent Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.51 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 8.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 30.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.37x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
TORNTPHARM Cash Flow Quality — Operating & Free Cash Flow
Torrent Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹3,023 Cr | ₹-3,292 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹2,585 Cr | ₹2,311 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹3,266 Cr | ₹3,186 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹2,368 Cr | ₹1,201 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1,803 Cr | ₹1,705 Cr | Positive Free Cash Flow | 8/10 |